All Online

1 - 3 of 3 results

Refine

Active filters

Insulin
Continuous Glucose Monitor Blood Sugar App
1 CME CREDIT

You know that insulin therapy is an important tool in improving quality of life and health outcomes for your patients with diabetes, but are you familiar with the expanding array of diabetes technology that can play an important role in improving insulin delivery and management? Do you know how to optimally use these tools? After this activity, you’ll be able to interpret continuous glucose monitoring data to improve time-in-range, minimize hypoglycemia, and reduce postprandial glycemic excursions. Don’t miss this opportunity to learn how to incorporate diabetes technology into clinical practice to optimize insulin management, bolster patients’ confidence in self-management of their diabetes, and, ultimately, improve health outcomes.


Woman Swiping Sensor With Smart Phone For Glucose Measurement
0.5 CME CREDIT

Patient Scenarios: Selecting and Implementing Digital Technology in Diabetes Care

An Interactive Case Experience

0.50 CME
0.50 CE | 0.50 Pharmacology

You know that insulin therapy is an important tool in improving quality of life and health outcomes for your patients with diabetes, but are you familiar with the expanding array of diabetes technology that can play an important role in improving insulin delivery and management? Do you know how to optimally use these tools? After this activity, you’ll be able to interpret continuous glucose monitoring data to improve time-in-range, minimize hypoglycemia, and reduce postprandial glycemic excursions. Don’t miss this opportunity to learn how to incorporate diabetes technology into clinical practice to optimize insulin management, bolster patients’ confidence in self-management of their diabetes, and, ultimately, improve health outcomes.


Woman looking at insulin pen while doctor looks at her
1 CME CREDIT

Updates from American Diabetes Association 2021

1.00 CME/MOC
1.00 AANP | 1.00 Pharmacology

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.